ICON plc Books Strong Q1 2026 Orders as Earnings Decline but Guidance Reaffirmed
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Icon ( (ICLR) ) just unveiled an update.
ICON plc reported its first-quarter 2026 results on June 23, 2026, highlighting its role as a major clinical research provider to global life sciences and public health organizations. The company combines deep operational and medical expertise to support drug and device development from early-stage molecule through to post-marketing support, reflecting its broad geographic footprint and diversified customer base.
For the quarter ended March 31, 2026, ICON posted revenue of $2,034.0 million, up 0.9% year on year, but saw margins and earnings decline versus the prior year. GAAP net income fell to $104.8 million, or $1.36 per diluted share, while adjusted EBITDA dropped 20.2% to $317.7 million and adjusted EPS declined to $2.50, as business mix and lower constant-currency growth weighed on profitability.
Commercially, ICON continued to build scale, generating gross bookings of $3,263 million and net business wins of $2,880 million in the quarter, yielding a net book-to-bill ratio of 1.42. This strong order intake lifted backlog to $22.7 billion, up 4.0% from the fourth quarter of 2025, underscoring solid demand trends despite near-term earnings pressure.
The company ended the quarter with cash and cash equivalents of $765.2 million and net debt of $2.6 billion, equating to a net debt-to-adjusted EBITDA ratio of 1.8x, supported by free cash flow of $136.2 million. Management reaffirmed its full-year 2026 financial guidance, signaling confidence in continued commercial momentum and execution of its strategic plan even as current-quarter profitability moderated.
The most recent analyst rating on (ICLR) stock is a Sell
with a $125.00 price target.
To see the full list of analyst forecasts on Icon stock,
see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Neutral.
Overall score is weighed down primarily by 2025 profitability compression and weaker cash-flow conversion, reinforced by earnings-call risks around restatements/control weaknesses and margin deterioration. Partially offsetting these are a relatively resilient balance sheet, constructive (but not fully long-term) technical trend, and moderate valuation (P/E ~23) despite no dividend yield support.
To see Spark’s full report on ICLR stock,
click here.
More about Icon
ICON plc is a Dublin-based, world-leading clinical research organization that provides integrated consulting, clinical development, commercialization and post-marketing solutions. The company serves pharmaceutical, biotechnology, medical device, government and public health clients worldwide, employing about 40,350 staff across 97 locations in 55 countries as of March 31, 2026.
Average Trading Volume: 1,143,017
Technical Sentiment Signal: Sell
Current Market Cap: $10.78B
See more insights into ICLR stock on TipRanks’ Stock Analysis page.
